ROMOSOZUMAB
Background and Date of Approval
Romosozumab is a humanised monoclonal antibody developed by Amgen Inc. and UCB Pharma. It received FDA approval on December 9, 2019. Romosozumab is indicated for the treatment of osteoporosis in postmenopausal women at high risk of fractures. The pivotal phase 3 FRAME study from 2016 demonstrated that romosozumab significantly reduces the risk of new vertebral fractures in postmenopausal women with osteoporosis. The study showed that romosozumab lowered the incidence of new vertebral fractures by 73% compared to placebo following 12 months of treatment.
Uses
Romosozumab is indicated for the treatment of the following: Osteoporosis in postmenopausal women at high risk of fracture Osteoporosis in men at high risk of fracture Bone density loss and fracture risk reduction in osteoporosis patients
How is it administered?
Romosozumab is administered via subcutaneous injection. The recommended dose is 210 mg once a month, given as two separate 105 mg injections in the upper arm, thigh, or abdomen. This monthly dosing regimen helps maintain effective levels of the drug in the body to provide ongoing therapeutic benefits.
Side Effects
Common side effects of Romosozumab include: Injection site reactions (pain, redness, swelling) Headache Musculoskeletal pain Serious side effects may include: Cardiovascular events such as myocardial infarction and stroke Severe allergic reactions Hypocalcemia (low calcium levels)
Warnings
Romosozumab carries a warning for potential cardiovascular events. Patients with a history of cardiovascular disease should be closely monitored for signs of heart attack or stroke. Additionally, there is a risk of hypocalcemia, which requires monitoring and appropriate management.
Precautions
Monitor cardiovascular health : Watch for increased risk of myocardial infarction, stroke, and cardiovascular death. Manage hypocalcemia : Check and correct serum calcium levels before starting treatment and during therapy. Prevent osteonecrosis of the jaw (ONJ) : Look out for symptoms of ONJ, particularly in patients with poor oral hygiene or those undergoing dental work. Check for delayed fracture healing : Observe patients with recent fractures for any signs of delayed healing or nonunion. Watch for allergic reactions : Be alert to symptoms of hypersensitivity reactions and respond appropriately. Avoid use during pregnancy and lactation : Do not use in pregnant or breastfeeding women due to potential risks.
Word of Advice
Before beginning Romosozumab treatment, patients should be made aware of its possible side effects and the importance of regular medical monitoring. Stress the need to follow the prescribed monthly injection schedule consistently for the best treatment results. Patients should promptly contact their healthcare provider if they develop any unusual symptoms, especially symptoms suggestive of cardiovascular problems or a serious allergic reaction. For additional guidance, refer to current clinical guidelines and reliable medical literature.
References
https://www.sciencedirect.com/topics/neuroscience/romosozumab https://www.ncbi.nlm.nih.gov/books/NBK585139/#:~:text=Romosozumab%20is%20a%20humanized%20monoclonal,formation%20while%20suppressing%20bone%20resorption . https://www.ncbi.nlm.nih.gov/books/NBK595381/
Frequently Asked Questions
How long is Romosozumab treatment typically recommended?
Romosozumab treatment is generally recommended for up to 12 months. After this period, most patients are transitioned to an antiresorptive therapy, such as bisphosphonates or denosumab, to maintain the bone density gained from Romosozumab treatment.
Can Romosozumab be used in men with osteoporosis?
Currently, Romosozumab is approved for the treatment of osteoporosis, specifically in postmenopausal women. Its use in men with osteoporosis is not yet widely approved, though clinical studies are ongoing to explore its effectiveness in male patients.
What should be avoided while receiving Romosozumab treatment?
Patients receiving Romosozumab should avoid engaging in activities that could increase their risk of falls or fractures, especially during the first few months of treatment. It's also important to avoid missing scheduled injections, as consistent monthly dosing is key to achieving and maintaining the benefits of treatment.